Evidence map›Paper›PMID 39061998›Full record

ArticleBiomedicines2024

Differential Impact of Tumor Endothelial Angiopoietin-2 and Podoplanin in Lymphatic Endothelial Cells on HCC Outcomes with Tyrosine Kinase Inhibitor Treatment According to Sex.

Simone Lasagni, Rosina Maria Critelli, Fabiola Milosa, Dario Saltini, Filippo Schepis, Adriana Romanzi, Francesco Dituri, Grazia Serino, Lorenza Di Marco, Alessandra Pivetti and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Simone LasagniGastroenterology Unit, Chimomo Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0002-8525-0898
Rosina Maria CritelliGastroenterology Unit, Chimomo Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Fabiola MilosaGastroenterology Unit, Chimomo Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0002-9869-8819
Dario SaltiniGastroenterology Unit, Chimomo Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0009-0007-3054-7575
Filippo SchepisGastroenterology Unit, Chimomo Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0001-6549-5102
Adriana RomanziGastroenterology Unit, Chimomo Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0001-7621-5778
Francesco DituriNational Institute of Gastroenterology "IRCCS Saverio de Bellis", Research Hospital, 70013 Castellana Grotte, Italy.
Grazia SerinoNational Institute of Gastroenterology "IRCCS Saverio de Bellis", Research Hospital, 70013 Castellana Grotte, Italy.ORCID 0000-0002-2971-0802
Lorenza Di MarcoClinical and Experimental Medicine Program, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0002-3716-7010
Alessandra PivettiGastroenterology Unit, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy.
Filippo ScianòGastroenterology Unit, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy.
Gianluigi GiannelliNational Institute of Gastroenterology "IRCCS Saverio de Bellis", Research Hospital, 70013 Castellana Grotte, Italy.ORCID 0000-0002-5140-8060
Erica VillaGastroenterology Unit, Chimomo Department, University of Modena and Reggio Emilia, 41125 Modena, Italy.ORCID 0000-0001-6388-7022

Funding

Italian Association for Cancer Research IG 2020‑ID. 24858Italian Medicines Agency TRS-2018-00001238Ministero della Salute RF-2016-02364053
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide. Curative treatments are available to a minority of patients, as HCC is often diagnosed at an advanced stage. For patients with unresectable and multifocal HCC, tyrosine kinase inhibitor drugs (TKIs) are the only potential treatment option. Despite extensive research, predictors of response to these therapies remain elusive. This study aimed to analyze the biological and histopathological characteristics of HCC patients treated with TKIs, focusing on angiogenesis and lymphangiogenesis. Immunohistochemistry quantified the expression of angiopoietin-2 (Ang2), lymphatic endothelial cells (LEC) podoplanin, and C-type Lectin Domain Family 2 (CLEC-2), key factors in neoangiogenesis and lymphangiogenesis. An increased expression of endothelial Ang2 and LEC podoplanin predicted a lower risk of metastasis. Female patients had significantly longer overall survival and survival on TKIs, associated with higher tumor expression of endothelial Ang2 and LEC podoplanin. Moreover, LEC podoplanin expression and a longer time on TKIs were independently correlated with improved survival on TKI therapy at Cox regression analysis. These findings suggest that endothelial Ang2 and LEC podoplanin could be potential biomarkers for predicting treatment outcomes and guiding therapeutic strategies in HCC patients treated with TKIs.

Indexed as

angiogenesisimmunohistochemistrylymphangiogenesismetastasissex

Identifiers

PMID39061998
PMCPMC11273995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.